Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… ·...
10
undefined S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2- NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide 1 / 20 Slide 2 / 20 Page 1
Transcript of Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… ·...
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 1 / 20
Slide 2 / 20
Page 1
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 3 / 20
Slide 4 / 20
Page 2
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 5 / 20
Slide 6 / 20
Page 3
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 7 / 20
Slide 8 / 20
Page 4
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 9 / 20
Slide 10 / 20
Page 5
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 11 / 20
Slide 12 / 20
Page 6
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 13 / 20
Slide 14 / 20
Page 7
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 15 / 20
Slide 16 / 20
Page 8
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 17 / 20
Slide 18 / 20
Page 9
undefined
S5-07 PRELIMINARY EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH PD-L1-POSITIVE, ESTROGEN RECEPTOR-POSITIVE (ER+)/HER2-NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028Speaker: Hope S Rugo
Slide 19 / 20
Slide 20 / 20
Page 10
